Marie Doussière

Dr. Marie Doussière

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CJClaire Jesson
Claire Jesson
YByohann bohbot
yohann bohbot
SSSimon Soudet
Simon Soudet
CRCedric Renard
Cedric Renard
JDJean-Marc Sobhy Danial
Jean-Marc Sobhy Danial
Vincent GoebVincent Goeb
Vincent Goeb
Cardiovascular disease, particularly myocardial infarction, is the leading cause of death of rheumatoid arthritis (RA) patients. The usefulness of the coronary artery calcification score (CACS), determined using cardiac computed-tomography (CT)-scan images, was assessed as a part of a cardiovascular work-up of RA patients at low or intermediate cardiovascular disease risk. This descriptive, cross-sectional, single-center study was conducted on patients with stable RA or that which is in remission. Each patient’s work-up included a collection of cardiovascular risk factors, laboratory analyses, an electrocardiogram, a supra-aortic trunks (SATs) echo-Doppler test and a cardiac CT scan. The primary endpoint was to determine the frequency of patients with a CACS > 100, indicating notable atherosclerosis. Fifty patients were analyzed: mean ± standard deviation age was 53.7 ± 7.5 years, 82% women. The CACS exceeded 100 in 12 (24%) patients (11 were at intermediate risk) and 2 of them underwent angioplasty for silent myocardial ischemia. Cardiovascular risk was reclassified from intermediate to high for 5 patients. Age according to sex and smoking status were significantly associated with that increase; no association was found with RA characteristics or treatments.

11 October 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DLDIEP Laetitia
DIEP Laetitia
VBVincent Barbier
Vincent Barbier
MDMarie Doussière
Marie Doussière
ETEstelle Touboul
Estelle Touboul
CJClaire Jesson
Claire Jesson
Vincent GoebVincent Goeb
Vincent Goeb
Background: Drug persistence reflects an agent’s efficacy and safety in routine practice. This study was undertaken to compare the 2-year persistence rates of three biologic disease-modifying antirheumatic drugs (bDMARDs) used to treat rheumatoid arthritis (RA) and to describe their efficacy and safety profiles. Methods: This retrospective, observational, single-center study included RA patients who had received at least one intravenous dose of infliximab, abatacept, and/or tocilizumab. Two-year drug persistence was estimated using the Kaplan–Meier method. Efficacy profiles were assessed as changes of Disease-Activity Score-28 (DAS28)-based EULAR-criteria responses. Results: The infliximab, abatacept, and tocilizumab groups included 40, 72, and 93 patients, respectively. Their respective 2-year persistence rates were similar: 55.0%, 45.8%, and 62.4%. Tocilizumab recipients benefited from greater improvement than those given infliximab (p = 0.0005) or abatacept (p < 0.0001). For all groups combined, 93.1% of patients obtained good or moderate EULAR responses. Conclusions: Even if this retrospective work includes different biases (lack of data, recruitment bias, etc.), it highlights that the 2-year persistence rates for infliximab, abatacept, and tocilizumab in daily practice did not differ significantly, thereby confirming the long-term efficacies of these three bDMARDs. However, tocilizumab was associated with more significant DAS28 improvement at 2 years than infliximab and abatacept.

8 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MDMarie Doussière
Marie Doussière
AAAhlem Aboud
Ahlem Aboud
GDGilles Dequen
Gilles Dequen
Vincent GoebVincent Goeb
Vincent Goeb
Background: Artificial intelligence (AI) is transforming medicine by supporting data-driven diagnosis, prognosis, and personalized care. In rheumatology, AI applications are rapidly expanding in imaging, disease monitoring, and therapeutic decision support. This review aimed to summarize current evidence on AI in osteoporosis and chronic inflammatory rheumatic diseases, with a focus on methodological robustness and clinical applicability. Methods: A narrative review was conducted following SANRA criteria. PubMed and the Cochrane Library were systematically searched for studies published between January 2015 and July 2025 using MeSH terms and free-text keywords related to AI, osteoporosis, and inflammatory rheumatic diseases. A total of 323 articles were included. Results: Machine learning and deep learning models show strong performance in osteoporosis for predicting bone mineral density (BMD), bone loss, and fractures. In chronic inflammatory rheumatic diseases, AI improves imaging interpretation, particularly for sacroiliitis. AI tools also demonstrate potential for predicting disease risk and activity, diagnostic support and treatment response. Hybrid models combining imaging, clinical, and biological data appear particularly promising. However, most studies rely on retrospective single-center datasets, with limited external validation, suboptimal explainability, and scarce evidence of real-world implementation. Conclusions: AI holds significant promise for advancing diagnosis and personalized management in osteoporosis and rheumatic diseases. However, major challenges persist, including heterogeneous data quality, inconsistent methodological reporting, limited clinical validation, and barriers to integration into routine practice. Bridging the gap between algorithmic performance and clinical impact will require prospective studies, robust validation frameworks, and strategies to build trust among clinicians and patients.

7 August 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CFCamille Farnos
Camille Farnos
VBVincent Barbier
Vincent Barbier
MDMarie Doussière
Marie Doussière
VDValentine Deprez
Valentine Deprez
YHYannis Hamidou
Yannis Hamidou
Vincent GoebVincent Goeb
Vincent Goeb
Background/Objectives: Janus kinase inhibitors (JAKis) belong to a new class of targeted oral drugs that have been added to the therapeutic arsenal for rheumatoid arthritis (RA). The aim of this study was to evaluate the efficacy and safety profiles of these four available molecules (tofacitinib, baricitinib, filgotinib, and upadacitinib) in real life. Methods: A retrospective, single-center observational study including all patients treated with JAKis for RA from 1 October 2017 to 1 December 2023. We assessed the maintenance rate at 24 months, which is an indirect reflection of the clinical and biological safety and efficacy profiles. Results: The 76 patients in our study were thus treated for the first time with anti-JAK, including 55 patients with baricitinib (BAR), 9 patients with tofacitinib (TOF), 4 patients with upadacitinib (UPA), and 8 patients with filgotinib (FIL). The majority of our patients had BAR introduced as the first intention. The therapeutic maintenance at 2 years for all our patients was 50%. The average maintenance duration was 8.6 months and was similar in all the groups. Of the 76 patients included in this study treated with Baricitinib (72.3%), 38 (50%) discontinued their treatment after two years of follow-up. Conclusions: Although this retrospective study is subject to various biases, it shows that the persistence rates of the four JAKi molecules in daily practice did not differ significantly, thus confirming the long-term efficacy of these drugs.

30 December 2022 in Rheumatology Advances in Practice
Verified
Journal Article
Open access
PDF file
MDMarie Doussière
Marie Doussière
JDJean-Marc Sobhy Danial
Jean-Marc Sobhy Danial
CBClémence Barthomeuf
Clémence Barthomeuf
JTJean-René Tesson
Jean-René Tesson
QBQuentin Beauvillain
Quentin Beauvillain
VGVincent Goeb
Vincent Goeb
Marie Doussiere, Jean-Marc Sobhy Danial, Clémence Barthomeuf, Jean-René Tesson, Quentin Beauvillain, Vincent Goeb; Diagnosis of Whipple’s disease with pseudo rh

24 May 2024 in Rheumatology Advances in Practice
Verified
Journal Article
Open access
PDF file
VMVanessa Moukarzel Vanessa Moukarzel
Vanessa Moukarzel Vanessa Moukarzel
MDMarie Doussière
Marie Doussière
VBVincent Barbier
Vincent Barbier
JMJimmy Menis
Jimmy Menis
LMLaure Le Monnier
Laure Le Monnier
VGVincent Goëb
Vincent Goëb
Objectives: PsA and gout are two prevalent rheumatic diseases, that can be associated as part of a rheumatism known as ‘Psout’. Both conditions are associated with cardiovascular (CV) risk, thus their co-occurrence could have significant implications for the management of CV risks and patient care. This study aimed to determine the prevalence of gout within a PsA patient cohort and, consequently, to identify factors associated with this pathological association. Methods: This is an observational, descriptive, cross-sectional, single-center study, including patients diagnosed with PsA. Demographic, clinical, biological and imaging data were collected. We identified the proportion of patients simultaneously affected by PsA and gout and compared characteristics between those with and without gout. Results: The prevalence of gout among PSA patients was 9.8% (12/122), with a prevalence of 23% for asymptomatic hyperuricemia and 7.4% presenting with specific US signs of gout. Significant associated factors in the univariate analysis included weight, hypertension, diabetes, certain medications (diuretics, aspirin, lipid-lowering agents), impaired renal function, elevated fasting blood glucose, lipid abnormalities and specific US signs of gout. Conclusion: Our study has described the existence of patients simultaneously affected by PsA and gout (‘Psout’). Performing joint US along with uric acid level measurements in PsA patients can enable personalized therapeutic care.